

**Aurealis Pharma to Discuss AUP-16 Clinical Development at the 27<sup>th</sup> European Wound Management Association Annual Meeting on May 3-5<sup>th</sup> 2017 in Amsterdam**

Basel Switzerland – April 26<sup>th</sup> 2017

Aurealis Pharma, a private biopharmaceutical company developing novel lactic acid bacteria based multitherapy biologics for patients with chronic inflammation and cancer, today announced that CMO Dirk Weber and CSO Thomas Wirth will attend the 27<sup>th</sup> European Wound Management Association (EWMA) Annual Meeting, the largest European-based conference for wound care, held in Amsterdam from May 3<sup>rd</sup> to 5<sup>th</sup> 2017. There will be a Focus Group meeting organized with international clinical wound care specialists on May 4<sup>th</sup> 2017 to discuss the status and clinical development of lead product AUP-16 in patients with Diabetic Foot Ulcers (DFU) and Venous Leg Ulcers (VLU).

“We are looking forward to attend EWMA and to have a focused, productive discussion with clinical experts about the status and clinical development plan for our lead product AUP-16 in DFU and VLU. Our AUP-16 program has made a lot of progress and it is exciting to discuss the design of the first-in-human studies planned to be initiated in 2018”, said CMO Dirk Weber. CSO Thomas Wirth added “After a very successful meeting at EWMA last year in Bremen, Germany, we are delighted to share the progress we made with AUP-16 with the internationally recognized clinical experts and to share and discuss our program and experience with AUP-16 in 1:1 meetings with other biotech and pharma companies being active in chronic wound care”.

The EWMA Annual Meeting is taking place for the 27<sup>th</sup> time this year and has become the largest European-based conference for scientists, clinical specialists and wound care companies focusing on the management and treatment of patients with chronic wounds. The EWMA conference offers high level scientific presentations, networking activities and an excellent opportunity to exchange knowledge and experiences with international colleagues from both ends, treating specialists and companies developing new treatment options for chronic wounds.

Aurealis Pharma is a Basel Switzerland and Kuopio Finland based privately-held biopharmaceutical company focusing on developing broadly applicable proprietary technology to effectively, safely and economically modulate and re-educate the distorted host immune microenvironment to proper state in chronic inflammation and cancer. Company’s technology is based on safe food-grade lactic acid bacteria delivering multiple human therapeutic proteins in target tissue to address the unmet medical need in chronic wounds and cancer.

For more information:

Juha Yrjänheikki, CEO

Aurealis Pharma

Tel: +358 45 8433550

Email: juha(at)aurealispharma.com

[www.aurealispharma.com](http://www.aurealispharma.com)



**AUREALIS PHARMA**

Hochbergerstrasse 60C

CH-4058 Basel

Switzerland

[www.aurealispharma.com](http://www.aurealispharma.com)

Microkatu 1

FI-70210 Kuopio

Finland